The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

NCT02473809 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide affects bone health in adults with diabetes complications and osteoporosis.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 60 people

Who can join Ages 30–90 · all sexes

Timeline Started 2015-08 · est. completion 2017-10

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02473809 ↗

Description as written by the study sponsor.

The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.

Treatments tested

Liraglutide also known as Victoza Drug

Once daily
Placebo also known as Saline Drug

Once daily

Main thing measured	Change in collagen I cross-linked C-terminal telopeptide measured in serum
Sponsor	University of Aarhus
Conditions studied	Diabetes Complications, Osteoporosis
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02473809 ↗